Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 126 - 150 of 1275 in total

Lamivudine

A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Approved
Investigational
Matched Description: … A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon …
Matched Categories: … Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor ... Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor …

Ritlecitinib

Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further...
Approved
Investigational
Matched Description: … This makes ritlecitinib a highly selective and irreversible JAK3 inhibitor. ... Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine …
Matched Categories: … Janus Kinase Inhibitor …

Naloxone

Naloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide. More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist,...
Approved
Vet approved

Ezetimibe

Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating...
Approved
Matched Categories: … Dietary Cholesterol Absorption Inhibitor …

Methylnaltrexone

Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008.
Approved
Matched Description: … It is also a weak CYP2D6 inhibitor. FDA approved in 2008. …

Mipomersen

Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. Mipomersen is indicated in...
Approved
Investigational
Matched Categories: … Apolipoprotein B-100 Synthesis Inhibitor …

Inclisiran

Inclisiran is a long-acting, synthetic small interfering RNA (siRNA) directed against proprotein convertase subtilisin-kexin type 9 (PCSK9), which is a serine protease that regulates plasma low-density lipoprotein cholesterol (LDL-C) levels. By binding to PCSK9 messenger RNA, inclisiran prevents protein translation of PCSK9, leading to decreased concentrations of PCSK9 and plasma...
Approved
Investigational
Matched Categories: … PCSK9 Inhibitor …

Leniolisib

Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of...
Approved
Investigational
Matched Description: … Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). …
Matched Categories: … Kinase Inhibitor …

Gemcitabine

Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed...
Approved
Matched Categories: … Nucleoside Metabolic Inhibitor …

Mercaptopurine

An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Approved
Matched Categories: … Nucleoside Metabolic Inhibitor …

Sulfadiazine

One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
Approved
Investigational
Vet approved

Dihydroergocristine

Dihydroergocristine is part of the ergoloid mixture products. It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline. To know more about ergoloid mixtures, please visit DB01049.
Approved
Experimental

Leflunomide

Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Approved
Investigational
Matched Description: … Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic …

Ouabain

A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase.
Approved
Matched Description: … It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase. …

Asciminib

Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein which serves as a driver of CML proliferation in most patients with the disease....
Approved
Investigational
Matched Description: … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995 ... Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive ... [A241065] Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket …

Azlocillin

Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.
Approved

Sulfacytine

Sulfacytine is a short-acting sulfonamide. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism...
Approved
Matched Description: … Sulfacytine is a competitive inhibitor of the enzyme dihydropteroate synthetase. …

Sulfisoxazole

A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
Approved
Vet approved

Piperacillin

Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.
Approved

Ampicillin

Ampicillin is a semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.
Approved
Vet approved

Oxacillin

An antibiotic similar to flucloxacillin used in resistant staphylococci infections.
Approved
Investigational

Voclosporin

Lupus nephritis (LN) is a type of glomerulonephritis occurring in patients with systemic lupus erythematosus (SLE). LN is a significant cause of renal failure, morbidity, and death in patients with SLE. Within 10 years of being diagnosed with SLE, 5-20% of those suffering from LN develop end-stage kidney disease, a...
Approved
Investigational
Matched Description: … [A227683] Voclosporin, marketed as Lupkynis, is a calcineurin-inhibitor immunosuppressant for the …
Matched Categories: … Calcineurin Inhibitor Immunosuppressant …

Lenacapavir

HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens.[A244170, A244175] Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 inhibition as a monotherapy in vitro, little to no cross-resistance...
Approved
Investigational
Matched Description: … [A244170, A244175] Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 …
Matched Categories: … Human Immunodeficiency Virus 1 Capsid Inhibitor …

Tacrine

A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market.
Approved
Investigational
Withdrawn
Matched Description: … A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants …

Stavudine

A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
Approved
Investigational
Matched Categories: … Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor …
Displaying drugs 126 - 150 of 1275 in total